Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI

Reuters12-17

Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI

Sagimet Biosciences Inc. has announced a global, exclusive license agreement with TAPI Technology & API Services (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd. Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient $(API)$ developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination (FDC) program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603338-en) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592992883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592992883","market":"nz","top_or_hot":-1,"title":"Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> has announced a global, exclusive license agreement with TAPI Technology &amp; API Services (TAPI), a subsidiary of <a href=\"https://laohu8.com/S/TEVJF\">Teva Pharmaceutical Industries Ltd.</a> Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient <a href=\"https://laohu8.com/S/API\">$(API)$</a> developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination (FDC) program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603338-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> has announced a global, exclusive license agreement with TAPI Technology &amp; API Services (TAPI), a subsidiary of <a href=\"https://laohu8.com/S/TEVJF\">Teva Pharmaceutical Industries Ltd.</a> Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient <a href=\"https://laohu8.com/S/API\">$(API)$</a> developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination (FDC) program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603338-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL701K4p:1","article_id":"2592992883","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592992883","pubTimestamp":1765972835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Inc. has announced a global, exclusive license agreement with TAPI Technology & API Services , a subsidiary of Teva Pharmaceutical Industries Ltd. Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient  developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination  program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4112":"金融交易所和数据","SGMT":"Sagimet Biosciences Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Sagimet Biosciences从TAPI获得创新Resmetirom API的全球许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SGMT":0.9},"content_text":"Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI\n    \n\nSagimet Biosciences Inc. has announced a global, exclusive license agreement with TAPI Technology & API Services (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd. Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient $(API)$ developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination (FDC) program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603338-en) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592992883","isCrawlerRequest":true}